Kymera therapeutics presents new preclinical data for kt-621, a first-in-class, oral stat6 degrader at the ats annual meeting

Kt-621, a potent, selective, oral stat6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ats annual meeting
ATS Ratings Summary
ATS Quant Ranking